Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
LOS ANGELES, CA, Dec. 07, 2017 -- US Nuclear Corp (OTCBB: UCLE) has signed a letter of intent with MIFTEC to become the exclusive contractor to manufacture medical isotope generators in the nuclear medicine market. MIFTEC’s parent company, MIFTI Nuclear Fusion, was recognized and awarded by the U.S. ARPA-E for their innovative approach and rapid progress towards fusion energy, which could provide a nearly limitless supply of clean, domestic power. MIFTI has shown that its Staged Z-Pinch fusion technique will produce high neutron flux, which in turn can be used to produce medical radioisotopes.
|
|||||
MIFTEC stated, “There is a terrible shortage of medical scanning isotopes. Millions of patients are unable to get the diagnostic scans and treatment they need due to the shortage and deteriorating sources of medical isotopes from Russia, Belgium, Canada, and South Africa.”
Currently, there are no suppliers in the USA.
MIFTEC’s breakthrough solution could solve this medical isotope shortage, and at a fraction of the cost. MIFTEC believes it can cut the current cost of producing radioisotopes by at least 50%, thereby allowing even greater access to individuals that need them.
US Nuclear Corp. is the exclusive manufacturer for these nuclear isotope generators.
- Global radioisotope production capacity is currently maxed out at $10 billion.
- Current global demand is significantly above $10 billion and is expected to reach $17 billion by 2021.
- Europe accounts for about 20% of the market, while North America is the dominant market for radioisotopes (45%). Currently there are no such manufacturers in the USA.
US Nuclear Corp. will also acquire a 10% interest in MIFTEC, and is working with BMA Securities to raise funds on a best efforts basis.
US Nuclear Corp. (OTCBB: UCLE) Robert I. Goldstein, President, CEO, and Chairman Ph: (818) 883 7043 Email: [email protected] www.usnuclearcorp.com
